ZA201207859B - 7-(1h-pyrazol-4-yl)-1,6-naththyridine compounds as syk inhibitors - Google Patents
7-(1h-pyrazol-4-yl)-1,6-naththyridine compounds as syk inhibitorsInfo
- Publication number
- ZA201207859B ZA201207859B ZA2012/07859A ZA201207859A ZA201207859B ZA 201207859 B ZA201207859 B ZA 201207859B ZA 2012/07859 A ZA2012/07859 A ZA 2012/07859A ZA 201207859 A ZA201207859 A ZA 201207859A ZA 201207859 B ZA201207859 B ZA 201207859B
- Authority
- ZA
- South Africa
- Prior art keywords
- naththyridine
- pyrazol
- compounds
- syk inhibitors
- syk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1007203.1A GB201007203D0 (en) | 2010-04-29 | 2010-04-29 | Novel compounds |
PCT/EP2011/056600 WO2011134971A1 (en) | 2010-04-29 | 2011-04-27 | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201207859B true ZA201207859B (en) | 2014-03-26 |
Family
ID=42289852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2012/07859A ZA201207859B (en) | 2010-04-29 | 2012-10-18 | 7-(1h-pyrazol-4-yl)-1,6-naththyridine compounds as syk inhibitors |
Country Status (17)
Country | Link |
---|---|
US (1) | US8633319B2 (en) |
EP (1) | EP2563789B1 (en) |
JP (1) | JP2013525405A (en) |
KR (1) | KR20130069653A (en) |
CN (1) | CN102947306A (en) |
AR (1) | AR081138A1 (en) |
BR (1) | BR112012027198A2 (en) |
CA (1) | CA2796954A1 (en) |
EA (1) | EA201290910A1 (en) |
ES (1) | ES2543426T3 (en) |
GB (1) | GB201007203D0 (en) |
MX (1) | MX2012012614A (en) |
SG (1) | SG184513A1 (en) |
TW (1) | TW201206925A (en) |
UY (1) | UY33359A (en) |
WO (1) | WO2011134971A1 (en) |
ZA (1) | ZA201207859B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2516434T1 (en) | 2009-12-23 | 2015-10-30 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
US9056873B2 (en) | 2011-06-22 | 2015-06-16 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
ES2691742T5 (en) | 2012-11-01 | 2022-03-18 | Infinity Pharmaceuticals Inc | Treatment of Cancers Using Modulators of PI3 Kinase Isoforms |
WO2014081616A1 (en) * | 2012-11-21 | 2014-05-30 | Merck Sharp & Dohme Corp. | Preparation of precursors for leukotriene antagonists |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US20160113932A1 (en) | 2013-05-30 | 2016-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
AU2014296184B2 (en) * | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN105940000B (en) | 2013-10-21 | 2019-12-24 | 盖诺斯克公司 | Substituted pyrimidine compounds and their use as SYK inhibitors |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3303348B1 (en) | 2015-05-28 | 2019-08-07 | Theravance Biopharma R&D IP, LLC | Naphthyridine compounds as jak kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
CA3123902A1 (en) * | 2019-01-03 | 2020-07-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for increasing transcription factor eb polypeptide levels |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
JP2023500906A (en) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | Methods of treating cancers with acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AR122928A1 (en) * | 2020-07-10 | 2022-10-19 | Goldfinch Bio Inc | 1,6-SUBSTITUTED NAPHTHYRIDINES INHIBITOR OF CDK5 |
WO2023102800A1 (en) * | 2021-12-09 | 2023-06-15 | Theravance Biopharma R&D Ip, Llc | Synthesis of 5, 7-dichloro-1, 6-naphthyridine |
WO2023193054A1 (en) * | 2022-04-07 | 2023-10-12 | Uniquest Pty Ltd | Spleen tyrosine kinase inhibitors |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH24267A (en) | 1980-02-15 | 1990-05-29 | Glaxo Group Ltd | Androstane carbothioates and pharmaceutical compositions containing the same |
AU570439B2 (en) | 1983-03-28 | 1988-03-17 | Compression Labs, Inc. | A combined intraframe and interframe transform coding system |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
US5889056A (en) | 1994-06-15 | 1999-03-30 | Glaxo Wellsome Inc. | Enzyme inhibitors |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
DE19723722A1 (en) | 1997-05-30 | 1998-12-10 | Schering Ag | Nonsteroidal progestogens |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6686145B1 (en) | 1997-12-17 | 2004-02-03 | Carnegie Mellon University | Rigidized trimethine cyanine dyes |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
US6255303B1 (en) | 1998-03-14 | 2001-07-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone PDE III/IV inhibitors |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (en) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
CO5180649A1 (en) | 1999-09-01 | 2002-07-30 | Abbott Lab | ANTAGONISTS OF GLUCOCORTICOID RECEPTORS FOR THE TREATMENT OF DIABETES FOR THE TREATMENT OF DIABETES |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
EP1305329B2 (en) | 2000-08-05 | 2015-03-18 | Glaxo Group Limited | 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyl)oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
WO2002026712A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
CN1678594A (en) | 2000-09-29 | 2005-10-05 | 葛兰素集团有限公司 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
ATE365720T1 (en) | 2001-03-08 | 2007-07-15 | Glaxo Group Ltd | AGONISTS OF BETA-ADRENORECEPTORS |
ATE381537T1 (en) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS |
BR0209271A (en) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Compound, use of a compound pharmaceutical composition, pharmaceutical aerosol formulation, method for treating a human or animal patient with an inflammatory and / or allergic condition, and process for preparing a compound |
US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
SI1425001T1 (en) | 2001-09-14 | 2009-04-30 | Glaxo Group Ltd Glaxo Welcome | Phenethanolamine derivatives for treatment of respiratory diseases |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US20030158195A1 (en) * | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
ES2298508T3 (en) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | GLUCOCORTICOID MIMETICS, METHODS TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS AND THEIR USES. |
CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (en) | 2002-04-02 | 2003-12-18 | Schering Ag | Quinoline and isoquinoline derivatives, a pharmaceutical agent and their use as anti-inflammatory agents |
DE60335869D1 (en) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1H-BENZO (F) INDAZOL-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
EP1497261B1 (en) | 2002-04-25 | 2007-12-19 | Glaxo Group Limited | Phenethanolamine derivatives |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
PT1521733E (en) | 2002-07-08 | 2014-10-29 | Pfizer Prod Inc | Modulators of the glucocorticoid receptor |
WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
PL375993A1 (en) | 2002-09-16 | 2005-12-12 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
US20070020253A1 (en) | 2002-10-16 | 2007-01-25 | David Williams | Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof |
AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
ATE390407T1 (en) | 2002-10-28 | 2008-04-15 | Glaxo Group Ltd | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
EP1699512B1 (en) | 2003-11-03 | 2012-06-20 | Glaxo Group Limited | A fluid dispensing device |
WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
WO2006038594A1 (en) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N-type calcium channel inhibitor |
MX2007004465A (en) | 2004-10-19 | 2007-05-07 | Hoffmann La Roche | Quinoline derivatives. |
ATE517908T1 (en) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | ANDROSTAN-17-ALPHA-CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS |
US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
JP2008535884A (en) | 2005-04-14 | 2008-09-04 | グラクソ グループ リミテッド | Indazole as a glucocorticoid receptor ligand |
GB0513297D0 (en) | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
GB0522880D0 (en) | 2005-11-09 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
PL2183254T3 (en) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
JP5754568B2 (en) * | 2008-08-05 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Naphthyridine substituted with 4-dimethylamino-phenyl and its use as a medicament |
EP2324022A1 (en) * | 2008-08-05 | 2011-05-25 | Boehringer Ingelheim International GmbH | Substituted naphthyridines and use thereof as medicines |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010070076A1 (en) | 2008-12-19 | 2010-06-24 | Crystax Pharmaceuticals, S.L. | Alkanoic acid derivatives and their therapeutic use as hdac inhibitors |
BRPI1006162A2 (en) | 2009-01-13 | 2019-09-24 | Glaxo Group Ltd | "compound, process for preparing a compound, pharmaceutical formulation, and use of a compound". |
SG175144A1 (en) | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
-
2010
- 2010-04-29 GB GBGB1007203.1A patent/GB201007203D0/en not_active Ceased
-
2011
- 2011-04-27 AR ARP110101455A patent/AR081138A1/en unknown
- 2011-04-27 MX MX2012012614A patent/MX2012012614A/en not_active Application Discontinuation
- 2011-04-27 KR KR1020127031384A patent/KR20130069653A/en not_active Application Discontinuation
- 2011-04-27 UY UY0001033359A patent/UY33359A/en not_active Application Discontinuation
- 2011-04-27 SG SG2012074845A patent/SG184513A1/en unknown
- 2011-04-27 EA EA201290910A patent/EA201290910A1/en unknown
- 2011-04-27 WO PCT/EP2011/056600 patent/WO2011134971A1/en active Application Filing
- 2011-04-27 US US13/642,338 patent/US8633319B2/en not_active Expired - Fee Related
- 2011-04-27 EP EP20110719781 patent/EP2563789B1/en active Active
- 2011-04-27 CA CA2796954A patent/CA2796954A1/en not_active Abandoned
- 2011-04-27 ES ES11719781.4T patent/ES2543426T3/en active Active
- 2011-04-27 BR BR112012027198A patent/BR112012027198A2/en not_active IP Right Cessation
- 2011-04-27 TW TW100114711A patent/TW201206925A/en unknown
- 2011-04-27 JP JP2013506640A patent/JP2013525405A/en active Pending
- 2011-04-27 CN CN2011800318413A patent/CN102947306A/en active Pending
-
2012
- 2012-10-18 ZA ZA2012/07859A patent/ZA201207859B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8633319B2 (en) | 2014-01-21 |
US20130040984A1 (en) | 2013-02-14 |
WO2011134971A1 (en) | 2011-11-03 |
MX2012012614A (en) | 2012-12-17 |
ES2543426T3 (en) | 2015-08-19 |
BR112012027198A2 (en) | 2016-07-19 |
UY33359A (en) | 2011-12-01 |
CA2796954A1 (en) | 2011-11-03 |
AR081138A1 (en) | 2012-06-27 |
TW201206925A (en) | 2012-02-16 |
GB201007203D0 (en) | 2010-06-16 |
CN102947306A (en) | 2013-02-27 |
EP2563789B1 (en) | 2015-05-20 |
SG184513A1 (en) | 2012-11-29 |
KR20130069653A (en) | 2013-06-26 |
JP2013525405A (en) | 2013-06-20 |
EA201290910A1 (en) | 2013-05-30 |
EP2563789A1 (en) | 2013-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201207859B (en) | 7-(1h-pyrazol-4-yl)-1,6-naththyridine compounds as syk inhibitors | |
IL245309B (en) | Tricyclic heterocyclic compounds as jak inhibitors | |
HRP20180139T1 (en) | Substituted pyridopyrazines as novel syk inhibitors | |
HK1218758A1 (en) | Compounds as c-met kinase inhibitors c-met | |
ZA201309128B (en) | Macrocyclic compounds as protein kinase inhibitors | |
EP2706852A4 (en) | Bipyridylaminopyridines as syk inhibitors | |
AP3391A (en) | 2-Amino-4-arylthiazole compounds as TROA1 antagonists | |
HK1180689A1 (en) | Imidazopyridines syk inhibitors syk | |
PL3031812T3 (en) | Chemical compounds | |
EP2717877A4 (en) | Organic compounds | |
IL229328A0 (en) | Compounds containing hydrido-tricyano-borate anions | |
ZA201206410B (en) | Polyheterocylic compounds highly potent as hcv inhibitors | |
EP2684886A4 (en) | Chromene compound | |
EP2725017A4 (en) | Chromene compound | |
ZA201309411B (en) | Anti-thrombotic compounds | |
IL235829A0 (en) | Triazolo compounds as pde10 inhibitors | |
HK1210178A1 (en) | Substituted pyridopyrazines as syk inhibitors syk | |
HK1208455A1 (en) | Triazole compounds as antivirals | |
PT2669278E (en) | Chromene compound | |
EP2781517A4 (en) | Nitrogenated heterocyclic compound | |
EP2669277A4 (en) | Chromene compound | |
EP2723173A4 (en) | Organic compounds | |
GB201004372D0 (en) | Compounds for purification | |
HK1191327A1 (en) | Azaspirodecanone compounds as hsl inhibitors hsl | |
EP2771011A4 (en) | Chemical compounds |